PITTSBURGH, April 20 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has been selected by the Clinton HIV/AIDS Initiative (CHAI) under its UNITAID-funded projects as the primary supplier of five antiretroviral (ARV) drugs used in second-line HIV/AIDS treatment regimens. Matrix also has been selected as the primary supplier of seven ARVs used for pediatric treatment.
Mylan Vice Chairman and CEO Robert J. Coury said: "I would like to congratulate UNITAID and CHAI on the tremendous impact they have made in fighting the HIV/AIDS epidemic, which continues to present significant challenges on a global scale. Facilitating patient access to affordable, quality treatments has helped transform AIDS from a fatal illness into a manageable chronic condition. Ensuring that access to these treatments continues to expand is a critical piece of solving this crisis. Mylan and Matrix are proud to play an important role in these efforts by supplying a broad portfolio of low cost, high quality products, and we remain committed to further increasing access for patients in developing countries through our innovative science and expertise."
According to the Joint United Nations Program on AIDS (UNAIDS), an estimated 33 million people in the world are infected with HIV, and more than 90% of those patients live in the developing world. Less than 4 million patients globally are receiving treatment; however, approximately 30% of patients in developing countries depend on Matrix ARV products.
Mylan's Chief Operating Officer Heather Bresch added: "Matrix has done a remarkable job developing a world-class ARV business in just a few years. Their emphasis on producing affordable products has significantly reduced the aver
|SOURCE Mylan Inc.|
Copyright©2009 PR Newswire.
All rights reserved